APR Applied Pharma Research SA

APR Applied Pharma Research SA specializes in developing and commercializing pharmaceutical products, particularly addressing unmet medical needs in rare and ultra-rare diseases. APR Applied Pharma Research SA focuses on pharmaceutical development, with headquarters in Switzerland. The company was acquired by HBM Partners in March 2015, although specific financial details were not disclosed. The CEO, Paolo Galfetti, leads the company, which has been involved in 2 deals to date.

Applied Pharma Research (APR) is dedicated to developing and commercializing innovative pharmaceutical products primarily for rare and ultra-rare diseases. The company’s core offerings include a range of patent-protected products designed to address unmet medical needs. Notable products include PKU GOLIKE, an advanced protein substitute for managing phenylketonuria (PKU), and Halykoo®, a line of healthcare solutions for infants. Additionally, APR markets SwitzAGE™, a nutraceutical range aimed at adult wellness.

These products utilize proprietary drug delivery technologies to enhance patient outcomes and are available across several European markets, including Italy, Germany, Switzerland, and Austria, through a global network of commercial partners, ensuring accessibility for patients and caregivers dealing with rare diseases. APR generates revenue through direct sales and partnerships across various markets. The firm's products, including the flagship PKU GOLIKE, are marketed directly via its sales teams in select European countries. Additionally, APR collaborates with pharmaceutical companies on a contract basis, providing research and development services.

This revenue model includes B2B transactions and fee-for-service agreements, catering to healthcare professionals, hospitals, and distributors, which supports the commercialization of APR's innovative products and fosters ongoing relationships with partners globally. APR intends to expand its product offerings by developing new solutions for rare diseases, with plans to launch these products by the end of 2024. The company aims to penetrate additional European markets and is particularly focused on expanding into Spain and France by 2025. The acquisition by HBM Partners in March 2015 is expected to support these initiatives, though specific financial terms were not disclosed.